OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Virginia Commonwealth University

6 Projects | 3 Researchers | $1,766,428 Invested

2023

Virginia Commonwealth University

Shijun Zhang, PhD

Probing neuroinflammation in Alzheimer's with NLRP3 PET radiotracers

  • Funding Amount: $600,000
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Target: Neuroinflammation
  • Status: Active

2016

Virginia Commonwealth University

Shijun Zhang, PhD

Target identification and mode of action studies for novel NLRP3 inflammasome inhibitors

  • Funding Amount: $130,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed

2015

Virginia Commonwealth University

Shijun Zhang, PhD

Development of novel NLRP3 inflammasome inhibitors towards Alzheimer's disease

  • Funding Amount: $160,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed

2013

Virginia Commonwealth University

James Bennett

Increasing Mitochondrial Biogenesis in Alzheimer's Disease

  • Funding Amount: $200,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Mitochondria/Metabolic Function
  • Status: Closed

2010

Virginia Commonwealth University

James Bennett

Safety/Tolerability and Effects on Cognitive Impairment, Impaired Cerebral Cortical Metabolism and Oxidative Stress of R(+)Pramipexole Administered to Subjects with Early Alzheimer's Disease

  • Funding Amount: $501,200
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Mitochondria/Metabolic Function
  • Status: Closed

2008

Virginia Commonwealth University

Michelle Block, PhD

NADPH Oxidase as a Therapeutic Target in Alzheimer's Disease

  • Funding Amount: $175,228
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed